Werewolf Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Werewolf Therapeutics, Inc. (HOWL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-70.52-37.37-53.81-49.98-15.04
Depreciation & Amortization1.813.401.100.740.15
Stock Based Compensation8.838.017.404.100.63
Change in Working Capital2.53-3.812.542.522.31
Change in Accounts Receivable1.355.58-6.930.000.00
Change in Accounts Payable3.46-4.343.051.010.39
Change in Other Working Capital-2.28-0.82-1.241.271.92
Other Operating Activities1.165.201.963.85-6.67
Net Cash from Operating Activities-56.19-32.61-40.60-42.88-18.62
Investing Activities
Capital Expenditures-0.250.77-3.610.50-0.56
Net Cash from Investing Activities-0.25-0.77-3.61-0.50-0.56
Financing Activities
Debt Repayment-10.000.000.000.000.00
Common Stock Issued23.5818.4215.99111.600.03
Other Financing Activities-0.500.00-0.09-2.38-0.34
Net Cash from Financing Activities13.0858.4315.91109.4393.86
Summary
Net Change in Cash-43.3625.05-28.3066.0574.67
Cash at Beginning of Period155.58130.53158.8392.780.00
Cash at End of Period112.2225.08130.53158.830.00
Free Cash Flow-56.44-33.38-44.21-43.37-19.18
Supplemental Disclosures
Interest Paid3.362.560.000.000.00